Ausgabe 3/2020
Inhalt (31 Artikel)
Radiology and nuclear medicine: advancing together in the era of precision medicine
Arturo Chiti, Yves Menu
Errare humanum est, sed in errare perseverare diabolicum: methodological errors in the assessment of the relationship between I-131 therapy and possible increases in the incidence of malignancies
Frederik A. Verburg, Martha Hoffmann, Ioannis Iakovou, Mark W. Konijnenberg, Jasna Mihailovic, Pablo Minguez Gabina, Petra Petranović Ovčariček, Cristoph Reiners, Alexis Vrachimis, Slimane Zerdoud, Luca Giovanella, Markus Luster
18F-FDG PET/CT in patients with post-transplant lymphoproliferative disorders: so far so good
Giorgio Treglia, Luca Ceriani
Letter to the Editor: 18F-NaF not cited in the EANM practice guideline for PET/CT imaging in medullary thyroid carcinoma
Paulo Schiavom Duarte
18F-Fluoride (18F-NaF) PET/CT in medullary thyroid carcinoma: far from evidence, far from guidelines!
Giorgio Treglia, Luca Giovanella
Diagnostic performance of FDG-PET/CT of post-transplant lymphoproliferative disorder and factors affecting diagnostic yield
F. M. Montes de Jesus, T. C. Kwee, X. U. Kahle, M. Nijland, T. van Meerten, G. Huls, R. A. J. O. Dierckx, S. Rosati, A. Diepstra, W. van der Bij, E. A. M. Verschuuren, A. W. J. M. Glaudemans, W. Noordzij
Chemokine receptor-4 targeted PET/CT with 68Ga-Pentixafor in assessment of newly diagnosed multiple myeloma: comparison to 18F-FDG PET/CT
Qingqing Pan, Xinxin Cao, Yaping Luo, Jian Li, Jun Feng, Fang Li
Assessment of the impact of 2015 American Thyroid Association guidelines in management of differentiated thyroid cancer patients
Sayak Choudhury, Archi Agrawal, Gouri Pantvaidya, Sneha Shah, Nilendu Purandare, Ameya Puranik, Venkatesh Rangarajan
Variations in radioiodine ablation: decision-making after total thyroidectomy
O. Maas, F. Forrer, M. Maas, C. M. Panje, J. Blautzik, M. Brühlmeier, I. Engel-Bicik, L. Giovanella, A. Haldemann, M. E. Kamel, S. Kneifel, C. Rottenburger, N. Schaefer, M. A. Walter, S. Weidner, P. M. Putora
Clinicopathologic risk factors of radioactive iodine therapy based on response assessment in patients with differentiated thyroid cancer: a multicenter retrospective cohort study
Seong Young Kwon, Sang-Woo Lee, Eun Jung Kong, Keunyoung Kim, Byung Il Kim, Jahae Kim, Heeyoung Kim, Seol Hoon Park, Jisun Park, Hye Lim Park, So Won Oh, Kyoung Sook Won, Young Hoon Ryu, Joon-Kee Yoon, Soo Jin Lee, Jong Jin Lee, Ari Chong, Young Jin Jeong, Ju Hye Jeong, Young Seok Cho, Arthur Cho, Gi Jeong Cheon, Eun Kyoung Choi, Jae Pil Hwang, Sang Kyun Bae
Superior performance of 18F-fluorocholine digital PET/CT in the detection of parathyroid adenomas
Diego Alfonso López-Mora, Marina Sizova, Montserrat Estorch, Albert Flotats, Valle Camacho, Alejandro Fernández, Safae Abouzian, Francisco Fuentes-Ocampo, José Ignacio Pérez Garcia, Ana Isabel Chico Ballesteros, Joan Duch, Anna Domènech, Antonio Moral Duarte, Ignasi Carrió
[18F]Fluciclovine PET/CT: joint EANM and SNMMI procedure guideline for prostate cancer imaging—version 1.0
Cristina Nanni, Lucia Zanoni, Tore Bach-Gansmo, Heikki Minn, Frode Willoch, Trond Velde Bogsrud, Ephraim Parent Edward, Bital Savir-Baruch, Eugene Teoh, Fenton Ingram, Stefano Fanti, David M. Schuster
18F-PSMA-1007 multiparametric, dynamic PET/CT in biochemical relapse and progression of prostate cancer
Christos Sachpekidis, A. Afshar-Oromieh, K. Kopka, D. S. Strauss, L. Pan, U. Haberkorn, A. Dimitrakopoulou-Strauss
Deep neural network for automatic characterization of lesions on 68Ga-PSMA-11 PET/CT
Yu Zhao, Andrei Gafita, Bernd Vollnberg, Giles Tetteh, Fabian Haupt, Ali Afshar-Oromieh, Bjoern Menze, Matthias Eiber, Axel Rominger, Kuangyu Shi
Digital versus analogue PET in [68Ga]Ga-PSMA-11 PET/CT for recurrent prostate cancer: a matched-pair comparison
Ian Alberts, George Prenosil, Christos Sachpekidis, Thilo Weitzel, Kuangyu Shi, Axel Rominger, Ali Afshar-Oromieh
68Ga-PSMA-11 PET/CT in patients with recurrent prostate cancer—a modified protocol compared with the common protocol
Fabian Haupt, Lotte Dijkstra, Ian Alberts, Christos Sachpekidis, Viktor Fech, Silvan Boxler, Tobias Gross, Tim Holland-Letz, Helle D. Zacho, Uwe Haberkorn, Kambiz Rahbar, Axel Rominger, Ali Afshar-Oromieh
The effect of androgen deprivation therapy on 68Ga-PSMA tracer uptake in non-metastatic prostate cancer patients
Cem Onal, Ozan Cem Guler, Nese Torun, Mehmet Reyhan, Ali Fuat Yapar
The role of additional late PSMA-ligand PET/CT in the differentiation between lymph node metastases and ganglia
Ian Alberts, Christos Sachpekidis, Lotte Dijkstra, George Prenosil, Eleni Gourni, Silvan Boxler, Tobias Gross, George Thalmann, Kambiz Rahbar, Axel Rominger, Ali Afshar-Oromieh
Impact of 68Ga-PSMA-11 PET staging on clinical decision-making in patients with intermediate or high-risk prostate cancer
Daniela A. Ferraro, Helena I. Garcia Schüler, Urs J. Muehlematter, Daniel Eberli, Julian Müller, Alexander Müller, Roger Gablinger, Helmut Kranzbühler, Aurelius Omlin, Philipp A. Kaufmann, Thomas Hermanns, Irene A. Burger
Prospective study on the effect of short-term androgen deprivation therapy on PSMA uptake evaluated with 68Ga-PSMA-11 PET/MRI in men with treatment-naïve prostate cancer
Otto Ettala, Simona Malaspina, Terhi Tuokkola, Pauliina Luoto, Eliisa Löyttyniemi, Peter J. Boström, Jukka Kemppainen
The management impact of 68gallium-tris(hydroxypyridinone) prostate-specific membrane antigen (68Ga-THP-PSMA) PET-CT imaging for high-risk and biochemically recurrent prostate cancer
Meghana Kulkarni, Simon Hughes, Andrew Mallia, Victoria Gibson, Jennifer Young, Ajay Aggarwal, Stephen Morris, Ben Challacombe, Rick Popert, Christian Brown, Paul Cathcart, Prokar Dasgupta, Victoria S. Warbey, Gary J. R. Cook
New insights in the paradigm of upregulation of tumoral PSMA expression by androgen receptor blockade: Enzalutamide induces PSMA upregulation in castration-resistant prostate cancer even in patients having previously progressed on enzalutamide
Florian Rosar, Sebastian Dewes, Martin Ries, Andrea Schaefer, Fadi Khreish, Stephan Maus, Hendrik Bohnenberger, Johannes Linxweiler, Mark Bartholomä, Carsten Ohlmann, Samer Ezziddin
The 68Ga/177Lu-theragnostic concept in PSMA-targeting of metastatic castration–resistant prostate cancer: impact of post-therapeutic whole-body scintigraphy in the follow-up
Johanna Maffey-Steffan, Lorenza Scarpa, Anna Svirydenka, Bernhard Nilica, Christian Mair, Sabine Buxbaum, Jasmin Bektic, Elisabeth von Guggenberg, Christian Uprimny, Wolfgang Horninger, Irene Virgolini
Clinical outcome of standardized 177Lu-PSMA-617 therapy in metastatic prostate cancer patients receiving 7400 MBq every 4 weeks
Sazan Rasul, Marcus Hacker, Elisabeth Kretschmer-Chott, Asha Leisser, Bernhard Grubmüller, Gero Kramer, Shahrokh Shariat, Wolfgang Wadsak, Markus Mitterhauser, Markus Hartenbach, Alexander R. Haug
225Ac-PSMA-617/177Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: pilot experience
Fadi Khreish, Niklas Ebert, Martin Ries, Stephan Maus, Florian Rosar, Hendrik Bohnenberger, Tobias Stemler, Matthias Saar, Mark Bartholomä, Samer Ezziddin
Planar scan vs. SPECT/low-dose CT for estimating split renal function by 99mTc-DMSA scintigraphy in children
Michala Holm Reichkendler, Ronan M. G. Berg, Robin de Nijs, Hanne Nørgaard, Ida Maria Schmidt, Lise Borgwardt
Extranodal involvement of multiple organs in diffuse large B cell lymphoma detected on 18F-FDG PET/CT
Tianbin Song, Rong Rong, Yusheng Su, Zhigang Liang, Jie Lu
Isolated involvement of thyroid gland by IgG4-related disease revealed by 18F-FDG PET/CT
Yuanyuan Jiang, Guozhu Hou, Wuying Cheng
Zirconium-89 labelled rituximab PET-CT imaging of Graves’ orbitopathy
Bart de Keizer, Kamil G. Laban, Rachel Kalmann
Correction to: The 68Ga/177Lu-theragnostic concept in PSMA-targeting of metastatic castration–resistant prostate cancer: impact of post-therapeutic whole-body scintigraphy in the follow-up
Johanna Maffey-Steffan, Lorenza Scarpa, Anna Svirydenka, Bernhard Nilica, Christian Mair, Sabine Buxbaum, Jasmin Bektic, Elisabeth von Guggenberg, Christian Uprimny, Wolfgang Horninger, Irene Virgolini